Search
Invex says its Presendin drug reduces headaches and improves visual acuity. Photo: James Yarema (Unsplash)

Invex raises $26m for clinical trials

Invex Therapeutics has received a $5 million investment from Andrew Forrest’s Tattarang as part of a share placement, with the proceeds to go towards the company’s research into neurological diseases.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Share Price

Closing price for the last 90 trading days
Powered by Morningstar ®

Top 10 Shareholders

Substantial shareholders as published in the annual report.
Powered by Morningstar ®

Total Shareholder Return as at 29/05/20

1 year TSR5 year TSR
thInvex Therapeutics
671 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Share Transactions

22/11/19
$0 Issued
22/11/19
$0 Issued
22/11/19
$0 Issued
Total value as at the date of the transaction
Powered by Morningstar ®

Revenue

190th-Invex Therapeutics$0
197 listed industrial companies ranked by revenue.
Powered by Morningstar ®